From Bioblast
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
News and Events | Working Groups | Short-Term Scientific Missions | Management Committee | Members |
COST Action CA15203 (2016-2021): MitoEAGLE
Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping
Scatena Roberto
MitoPedia topics: EAGLE
COST: Member COST WG1: WG1 COST WG2: WG2 COST WG3: WG3 COST WG4: WG4 COST Mentor: Mentor
Name | Scatena Roberto, Prof. PhD |
---|---|
Institution | Department of Diagnostics and Laboratory Medicine,
Institute of Biochemistry and Clinical Biochemistry, Polyclinic A. Gemelli - Catholic University, IT |
Address | Largo A. Gemelli 8, 00168 |
City | Rome |
State/Province | |
Country | Italy |
[email protected] | |
Weblink | |
O2k-Network Lab | IT Rome Scatena R |
New Open Access Journal
- Dr. R. Scatena is the editor of 'Cancer Stem Cells'.
Labels:
Field of research: Basic
Publications
Published | Reference | |
---|---|---|
BEC 2020.1 doi10.26124bec2020-0001.v1 | 2020 | Gnaiger E et al ― MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1. https://doi.org/10.26124/bec:2020-0001.v1 |
Bottoni 2019 Adv Exp Med Biol | 2019 | Bottoni P, Scatena R (2019) Mitochondrial metabolism in cancer. A tangled topic. Which role for proteomics? Adv Exp Med Biol 1158:1-16. |
Scatena 2019 Curr Med Chem | 2019 | Scatena R, Bottoni P (2019) The tangled mitochondrial metabolism in cancer: An innovative pharmacological approach. Curr Med Chem 27:2106-17. |
Tesori 2015 Sci Rep | 2015 | Tesori V, Piscaglia AC, Samengo D, Barba M, Bernardini C, Scatena R, Pontoglio A, Castellini L, Spelbrink JN, Maulucci G, Puglisi MA, Pani G, Gasbarrini A (2015) The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Sci Rep 5:9149. |
Scatena 2012 Adv Exp Med Biol | 2012 | Scatena R, Bottoni P, Giardina B (eds) (2012) Advances in mitochondrial medicine. Adv Exp Med Biol 942:p461. |
Abstracts
Published | Reference | |
---|---|---|
Scatena 2018 MiP2018 | 2018 | No abstract. |
Scatena 2017 Abstract MITOEAGLE Barcelona | 2017 | Mitochondria and cancer stem cells in hepatocarcinoma. An illustrative example of a tangled methodological approach. |
Scatena 2017 MITOEAGLE Obergurgl | 2017 | Cancer stem cell differentiation induced by PPAR ligands. Which role for an inhibition of mitochondrial respiratory chain? |
MitoEAGLE Feedback
- Specifically, we are studying mitochondrial metabolism in cancer cells. At this aim we are also participating to mt-HPP project, an Italian consortium whose target is a definition of mitochondrial proteome in health and disease. Briefly, my specific activity is to compare mitochondrial functional status with the mitochondrial proteome picture in different human cell line. I do think that a "contact" between these two important initiatives should be useful for both.
- Moreover, to stress the potential translational applications of research on bioenergetics in general and on mitochondria in particular (as also recently highlighted by Paolo Bernardi during EBEC 2016), I would like to suggest to begin to think to a careful pathophysiological classification of all mitochondriopathies (inborn and acquired, primary and secondary, ECR of metabolic related and so on) to reinforce the concept of a “mitochondrial medicine”, concept, until now, too often neglected with dramatic consequences. - Scatena Roberto (2016).